ZBH Stock Overview
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Zimmer Biomet Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$111.55 |
| 52 Week High | US$134.15 |
| 52 Week Low | US$96.74 |
| Beta | 1.02 |
| 1 Month Change | -5.83% |
| 3 Month Change | -0.76% |
| 1 Year Change | -11.01% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -16.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZBH | AT Medical Equipment | AT Market | |
|---|---|---|---|
| 7D | -1.1% | 1.8% | 1.6% |
| 1Y | -11.0% | 2.1% | 3.7% |
Price Volatility
| ZBH volatility | |
|---|---|
| ZBH Average Weekly Movement | 2.9% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in AT Market | 5.2% |
| 10% least volatile stocks in AT Market | 1.6% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1927 | 18,000 | Ivan Tornos | www.zimmerbiomet.com |
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products.
Zimmer Biomet Holdings, Inc. Fundamentals Summary
| ZBH fundamental statistics | |
|---|---|
| Market cap | €22.94b |
| Earnings (TTM) | €954.57m |
| Revenue (TTM) | €6.89b |
24.0x
P/E Ratio3.3x
P/S RatioIs ZBH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZBH income statement (TTM) | |
|---|---|
| Revenue | US$7.39b |
| Cost of Revenue | US$2.08b |
| Gross Profit | US$5.31b |
| Other Expenses | US$4.29b |
| Earnings | US$1.02b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | 4.98 |
| Gross Margin | 71.82% |
| Net Profit Margin | 13.85% |
| Debt/Equity Ratio | 47.9% |
How did ZBH perform over the long term?
See historical performance and comparison